Cardiovascular event rates in the MOSAIC trial: 2-year follow-up data

Area of Science:

• Cardiology
• Sleep Medicine
• Clinical Trials

Background:

• The MOSAIC trial assessed continuous positive airway pressure (CPAP) effects on sleepiness and cardiovascular risk in minimally symptomatic obstructive sleep apnea (OSA) patients over six months.
• While CPAP improved Epworth Sleepiness Scores, it did not significantly impact blood pressure or predicted vascular risk.

Discussion:

• This follow-up study analyzed 2-year vascular event rates in 188 MOSAIC trial participants.
• A statistically weak but significant reduction in vascular events was noted with CPAP (p=0.049), with 25 total events and 4 deaths observed.
• These findings highlight the need for larger trials to ascertain CPAP's definitive impact on vascular events and mortality in this population.

Key Insights:

• CPAP effectively reduces sleepiness in minimally symptomatic OSA patients.
• No significant improvement in blood pressure or predicted vascular risk was seen after six months of CPAP.
• A trend towards reduced vascular events with CPAP warrants further investigation in larger studies.

Outlook:

• Future large-scale randomized trials are essential to confirm if CPAP reduces actual vascular events in minimally symptomatic OSA.
• Power calculations suggest approximately 2540 patients are needed for trials targeting vascular event reduction and over 6000 for mortality endpoints.
• Further research should focus on long-term cardiovascular outcomes and optimal CPAP treatment strategies for OSA patients.